TTFields Therapy Offers New Hope in Metastatic Non-Small-Cell Lung Cancer Treatment: Insights from the LUNAR Phase 3 ...
What are your thoughts on the overall impact of TTFields treatment on the lives of patients with lung cancer?
What are the ongoing challenges and areas for future research in the use of TTFields for lung cancer?
Essential Thrombocythemia: Diagnosis, Risk- [slides 2023]
Niraparib Treatment in Patients With Advanced Ovarian Cancer
Neoadjuvant Chemo: Insights & Its Role in Cancer Care
Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Sacituzumab Govitecan: A New Dawn in Cancer Care
Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties...
Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEnglandLDN #TesticularCancer #Cancer #Research The Impact Of A S...
Vered Stearns, MD @VeredStearns @hopkinskimmel #BreastCancer #Cancer #Research Talking An Individualized Approach To ...
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic ...
Advancements in Bispecific Antibodies [2023 slides]
Potential of JAK Inhibitors in Myelofibrosis [2023 slides]
Relapse Refractory Hodgkin lymphoma [slides 2023]
Pacritinib: Anemia Mechanisms in MPNs -NFKB/ACVR1- [2023 SLIDES]
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
Advertise on Oncology: Book Now for Limited Time Discounts
Ghassan Abou-Alfa, MD - HIMALAYA Phase III trial - Tremelimumab accepted under Priority Review in the US for patients...
TROP2 ADC in NSCLC [2023] slides Sai-Hong Ignatius Ou, MD - MOASC
RxPONDER trial (SWOG S1007) Yara Abdou SABCS 2022
Updates in Lymphoma [2023] Interview - Elizabeth Brem, MD - MOASC
Updates in Head and Neck Cancer [2023] Interview - Shirin Attarian, MD - MOASC
Updates in GU [2023] Interview - Mar, MD - MOASC
Updates in Breast Cancer [2023] Interview - Lavasani, MD MOASC
FLAURA2: Should this Positive Trial Change Practice for EGFRm+ NSCLC
IMpower010 Unveiled: A Fresh Look at Atezolizumab in Lung Cancer
Is the Oncology Community Too Accepting of Marketing Messages in Cancer Trials? A Close Look at IMpower010
ASCO 2023 Top 5 Lung Abstracts Reviewed Jack West, MD
Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data
I-SPY2 HER2+ and HER2- Precisely ID'd with 53 Gene Signatures
Bevacizumab FOLFOXIRI - Atezolizumab Metastatic Colorectal Cancer
BRCA1, BRCA2 or PALB2 in pancreatic cancer.